Sign In
Buy GERN
$1.42
-0.0800 (-5.33%)
At Close: Jul 13, 2026
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
08:00am, Monday, 13'th Jul 2026
Mr. Rath brings senior leadership experience in business development across a range of biopharmaceutical companies Mr. Rath brings senior leadership experience in business development across a range o
Geron Corporation: Commercial Performance Could Dovetail With IMpactMF Run-Up
10:11am, Wednesday, 01'st Jul 2026
Geron Corporation delivered Q1'26 Rytelo revenues of $51.8M, up 8% sequentially, with two consecutive quarters of demand growth. GERN maintained 2026 guidance, with net product revenues of $220M-$240M
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Thursday, 18'th Jun 2026
FOSTER CITY, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective June 17, 2026, it granted stock op
Geron Corporation (GERN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
11:38am, Monday, 08'th Jun 2026
Geron Corporation (GERN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
After Plunging 26.6% in 4 Weeks, Here's Why the Trend Might Reverse for Geron (GERN)
10:36am, Thursday, 04'th Jun 2026
Geron (GERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ear
Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
08:00am, Monday, 01'st Jun 2026
FOSTER CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, tod
Geron: Time To Reconsider This Oversold Biotech
05:53am, Monday, 01'st Jun 2026
Geron has secured FDA approval for RYTELO in low- to intermediate-1 risk MDS, marking a pivotal milestone after decades of development. Despite disappointing initial RYTELO sales, GERN forecasts 2026
Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Tuesday, 19'th May 2026
Geron (GERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ear
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Monday, 18'th May 2026
FOSTER CITY, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective May 15, 2026, it granted stock opti
Geron Corporation (GERN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
11:30pm, Tuesday, 12'th May 2026
Geron Corporation (GERN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026
09:31am, Tuesday, 12'th May 2026
Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population
Geron Corporation (GERN) Q1 2026 Earnings Call Transcript
04:21pm, Wednesday, 06'th May 2026
Geron Corporation (GERN) Q1 2026 Earnings Call Transcript
Geron (GERN) Reports Q1 Loss, Beats Revenue Estimates
09:25am, Wednesday, 06'th May 2026
Geron (GERN) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.03 per share a year ago.
Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights
07:00am, Wednesday, 06'th May 2026
Achieved $51.8 million in RYTELO ® (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025 Reiterated 2026 RYTELO net product revenue and total operating ex
Geron Plans to Present at Upcoming Investor Conferences
08:00am, Tuesday, 05'th May 2026
FOSTER CITY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, toda
